PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2022; 11(04): 346-352
DOI: 10.1055/s-0042-1742593
Original Article
Leukemia, Lymphoma, Myeloma

Dysregulated Expression of MiR-19b, MiR-25, MiR-17, WT1, and CEBPA in Patients with Acute Myeloid Leukemia and Association with Graft versus Host Disease after Hematopoietic Stem Cell Transplantation

Mahdiyar Iravani Saadi
1   Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran
,
Fatemeh Tahmasebijaroubi
2   Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
,
Esmat Noshadi
2   Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
,
Raha Rahimikian
3   Department of Biochemistry, Bushehr University of Medical Sciences, Bushehr, Iran
,
Zahed Karimi
4   Hematology and Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
,
Maryam Owjfard
5   Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
6   Shiraz University of Applied Science and Technology (UAST), Shiraz, Iran
,
Ahmad Niknam
2   Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
,
Ehsan Nabi Abdolyousefi
2   Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
,
Sanaz Salek
2   Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
,
Reza Tabrizi
7   Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
8   Non Communicable Diseases Research Center (NCDC), Fasa University of Medical Sciences, Fasa, Iran
,
Elham Jamali
2   Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
› Institutsangaben
Funding Dr. Elham Jamali reports this work was financially supported by Shiraz University of Medical Sciences, Shiraz, Iran and grants from grant number 94–01–104–11279.
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

Abstract

Zoom
Elham Jamali

Objectives Acute myeloid leukemia (AML) is a blood malignancy characterized by the proliferation of aberrant cells in the bone marrow and blood that interfere with normal blood cells. We have investigated whether changes in the level of micro-ribonucleic acid (miR)-19b, miR-17, and miR-25, Wilms' tumor (WT1), and CCAAT enhancer-binding protein α (CEBPA) genes expression affect disease prognosis and clinical outcome in AML patients.

Materials and Methods The expression level of miR-19-b, miR-17, and miR-25, as well as WT1 and CEBPA genes in a group of patients and controls as well as different risk groups (high, intermediate, and favorite risk), M3 versus non-M3, and graft-versus-host disease (GvHD) versus non-GvHD patients were assessed using a quantitative SYBR Green real-time polymerase chain reaction method.

Results When compared with the baseline level at the period of diagnosis before chemotherapy, the expression of miR-19b and miR-17 in AML patients increased significantly after chemotherapy. The level of miR-19b and miR-25 expression in AML patients with M3 and non-M3 French–American–British subgroups differ significantly. MiR-19b and miR-25 expression was elevated in GvHD patients, while miR-19b and miR-25 expression was somewhat decreased in GvHD patients compared with non-GvHD patients, albeit the difference was not statistically significant. Also, patients with different cytogenetic aberrations had similar levels of miR-19-b and miR-25 expression.

Conclusion MiR-19b, miR-17, and miR-25 are aberrantly expressed in AML patients' peripheral blood leukocytes, which may play a role in the development of acute GvHD following hematopoietic stem cell transplantation.

Keywords

acute myeloid leukemia - microRNA - chemotherapy - stem cell transplantation - acute graft versus host disease


Publikationsverlauf

Artikel online veröffentlicht:
25. April 2022

© 2022. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India